On 29 April 2020, we have received a positive decision from the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPLWMiPB) regarding an innovative GPR40 receptor agonist – CLP207280.
The clinical programme will be conducted in the treatment of metabolic diseases, including type II diabetes and diabetic neuropathies. The aim of the study will be to determine the safety and tolerability of the drug, as well as its pharmacokinetic properties after single and repeated administration and its interaction with metformin and food.
The drug is characterised by an extremely favourable safety profile in toxicological and preclinical studies, which distinguishes it from other drugs in this class.
The study is carried out as part of the GATE project, for which the Company was subsidised from the National Centre for Research and Development (POIR) in the amount of PLN 24.7 million.